HomeStock ListAstellas Pharma Inc

Astellas Pharma Inc

Closed

1,578 -1.13

Overview

Share price change

24h

Current

Min

1567

Max

1597

Key metrics

By Trading Economics

Income

-35B

-1.5B

Sales

30B

422B

P/E

Sector Avg

35.271

EPS

10.4

Dividend yield

2.792

Profit margin

-0.372

EBITDA

-33B

36B

Dividends

By Dow Jones

Dividend Yield

Sector avg

2.79%

Next earnings

25 Apr 2024

Market Stats

By TradingEconomics

Market Cap

-93B

2.9T

Previous open

1579.13

Previous close

1578

News Sentiment

By Acuity

11%

89%

Astellas Pharma Inc chart

Related News

7 Aug 2023, 14:26 UTC

Major Market Movers

Poseida Therapeutics Shares Leap on Astellas Investments

1 May 2023, 00:42 UTC

Acquisitions, Mergers, TakeOvers

Astellas Pharma to Buy Iveric Bio for About $5.9 Billion

28 Aug 2023, 05:18 UTC

Acquisitions, Mergers, TakeOvers

Novartis: Mycamine Is Antifungal Treatment

28 Aug 2023, 05:16 UTC

Acquisitions, Mergers, TakeOvers

Novartis: Sandoz Completes Acquisition of Mycamine Brand From Astellas

Astellas Pharma Inc forecast

Sentiment

By Acuity

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Astellas Pharma Inc

Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.